• Advanced hepatocellular carcinoma: More treatments options ahead

    Transarterial chemoembolization and external radiation therapy have been extensively investigated in combination for improved survival for this stage. However, recent trial shows that HCC patients with vascular invasion might benefit from such a combination as well.

  • Atezolizumab and chemotherapy approach for NSCLC with squamous epithelial histology

    Patients with advanced non-small cell lung cancer (NSCLC) with squamous epithelial histology may benefit from an additional dose of the PD-L1 inhibitor atezolizumab in addition to chemotherapy in first-line treatment compared to chemotherapy alone.

  • Exoskeletons at the workplace: blessing or curse?

    The number of injury-related work absences and the rising reasons behind them is raising concerns. Exoskeletons could be of help to protect a worker's health, but how secure are these complex systems?

  • Vitamins B6 and B12 raise the risk of lung cancer in men

    Vitamin supplements are also widely used in many European countries. However, a US study showed that vitamins B6 and B12, taken as individual nutritional supplements, may have a role in male lung cancer incidence.

  • Google seeks to expand into digital health

    Google is a crucial bidder for Nokia Healthcare, a Nokia subdivision focusing on smart health-related products.

  • Higher tumor mutation burden predicts better response to checkpoint inhibitors

    A recent issue of the New England Medical Journal features a study which tested two new biological agents, nivolumab, and ipilimumab, against chemotherapy in a specific population of non-small-cell lung cancer patients - those with a high tumor mutation burden (TMB).

  • Methotrexate in early rheumatoid arthritis: Are higher doses not superior to low-dose therapies?

    Recent data questions high dose usage in the early therapy phases for rheumatoid arthritis (RA) with oral methotrexate (MTX).

  • Link found between breast implants and anaplastic large cell lymphoma

    Awareness of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) began to rise in 2011 when the FDA released a report on some of these cases. Since then, several studies confirmed this interlink with a recent Dutch population-based, case-control study adding crucial insights into it.

  • Increased risk for heart failure within 6 weeks after giving birth

    A study from the University of Illinois at Chicago has found that women are at the highest risk for heart failure within the six weeks after delivery, known as the postpartum period.

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as Ibuprofen may be able to prevent Alzheimer’s

    Scientists have proposed that once individuals at risk of developing Alzheimer’s have been identified, a low-dose ibuprofen prophylaxis can be started to stop Alzheimer’s in its tracks.

  • US medical school launches early phase HIV vaccine clinical trial

    Based on the available scientific knowledge and pre-clinical evidence, the University of Massachusetts Medical School has initiated multicenter, phase I clinical trial to investigate an HIV vaccine that might prevent HIV infection.

  • Parkinson's: Skin test enables early diagnosis

    Scientists succeeded in detecting Parkinson's disease through a minimally invasive skin biopsy - years before the patient becomes noticeably ill.

  • Coronary stenting with stable CHD: no advantages over placebo?

    Percutaneous Coronary Interventions (PCI) play a major role in cardiology, as they are the gold standard for the treatment of narrowed (stenosed) coronary vessels. However, the highly acclaimed stents are the target of new criticism.

  • Anakinra helps stroke patients reduce harmful inflammation

    The drug anakinra has been found to reduce harmful inflammation in the early stages of stroke, according to fresh research from Manchester University and the Salford Royal NHS Foundation.

  • Making vaccines more efficient

    Researchers have discovered a new mechanism by which live vaccines induce immunity. Molecules produced exclusively by live microorganisms are recognized by specialized receptors of the immune system, subsequently triggering a protective immune response.

  • Are NOACs an option for cancer patients?

    Two recent studies suggest that NOACs promise better prophylaxis when compared to heparin standard use. On the other hand, the risk of bleeding is higher among NOACs. At a state-of-the-art symposium at GTH in Vienna, Prof. Dr. Anne Angelillo-Scherrer, University Clinic of Hematology and Central Hematology Laboratory Bern, presented which patients might be eligible for NOACs.

  • Sugary drinks increase the risk of type 2 diabetes

    The frequent consumption of sugary drinks is known to cause overweight and obesity and can contribute to an increased risk of type 2 diabetes. The replacement with calorie-free drinks with artificial sweeteners is no alternative, as these drinks also increase the risk of diabetes.

  • Vaginal microbiome and HIV infections

    Dysbiosis of the vaginal bacterial flora is a key factor in vaginal inflammation, in the consistency of the epithelial barrier, and for the acquisition of HIV infection. Nichole Klatt, from the University of Washington, Seattle, presented current findings on the influence of vaginal microbiome on HIV transmission at the 25th CROI in Boston on March 6, 2018.

  • Is a stool sample sufficient for diagnosing Crohn's disease?

    An international research group led by Victoria Pascal from the Department of Gastroenterology, Vall d'Hebron Research Institute in Barcelona, has succeeded in identifying patients with Crohn's disease (CD) solely from stool samples.

  • Von Willebrand factor: more than carriers of factor VIII

    The Von Willebrand Factor (VWF) is a carrier protein of blood coagulation factor VIII and captures platelets at locations with vascular damage. It undergoes conformational changes within the A1 domain and through the development of the A2 domain. Its size and function are regulated by the metalloproteinase ADAMTS13. ADAMTS13 deficiency can, therefore, lead to the life-threatening disease thrombotic thrombocytopenic purpura (TTP).

  • 82 |
  • 83 |
  • 84 |
  • 85 |
  • 86 |
  • 87 |
  • 88 |
  • 89 |
  • 90 |
  • 91 |
  • 92 |